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Abstract
Background: Stakeholder engagement has become widely accepted as a necessary component of guideline
development and implementation. While frameworks for developing guidelines express the need for those
potentially affected by guideline recommendations to be involved in their development, there is a lack of
consensus on how this should be done in practice. Further, there is a lack of guidance on how to equitably and
meaningfully engage multiple stakeholders. We aim to develop guidance for the meaningful and equitable
engagement of multiple stakeholders in guideline development and implementation.
Methods: This will be a multi-stage project. The first stage is to conduct a series of four systematic reviews. These will (1)
describe existing guidance and methods for stakeholder engagement in guideline development and implementation, (2)
characterize barriers and facilitators to stakeholder engagement in guideline development and implementation, (3)
explore the impact of stakeholder engagement on guideline development and implementation, and (4) identify issues
related to conflicts of interest when engaging multiple stakeholders in guideline development and implementation.
Discussion: We will collaborate with our multiple and diverse stakeholders to develop guidance for multi-stakeholder
engagement in guideline development and implementation. We will use the results of the systematic reviews to develop
a candidate list of draft guidance recommendations and will seek broad feedback on the draft guidance via an online
survey of guideline developers and external stakeholders. An invited group of representatives from all stakeholder groups
will discuss the results of the survey at a consensus meeting which will inform the development of the final guidance
papers.
Our overall goal is to improve the development of guidelines through meaningful and equitable multi-stakeholder
engagement, and subsequently to improve health outcomes and reduce inequities in health.
Keywords: Guidelines, Stakeholder engagement, Coproduction, Systematic reviews, Guidance, Equity, Integrated
knowledge translation
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Contribution to the literature
 Existing guidance on stakeholder engagement largely
focuses on patient, consumer, caregiver, or family
involvement in guideline development but does not
provide guidance on multi-stakeholder engagement.
 The MuSE project will compile and provide
evidence-based strategies for the equitable and
meaningful engagement of multiple stakeholders
during the guideline development and implementa-
tion process.
 The MuSE project will develop a stakeholder
engagement plan for its own project stakeholders
and evaluate its development and implementation.
Background
Guidelines from various entities exist for many health
conditions and health-related activities. Guidelines con-
tain recommendations for health practice, public health,
or health policy [1]. They are used by health care pro-
viders as well as policymakers, health system leaders,
professional medical bodies, service organizations, fun-
ders, and regulatory authorities [2]. Recommendations
in guidelines should be based on available research evi-
dence [3]. Guideline development requires evaluating,
summarizing, and making recommendations based on
the available body of evidence regarding patient care,
public health, and health systems. This requires weigh-
ing the benefits and risks that accompany all care and
policy options before making recommendations [3]. Son-
nad [4] noted that a lack of connection between guide-
line developers and those who use them often leads to
controversy and uncertainty. Indeed, engaging guideline
users during the guideline development process has been
noted to improve guideline recommendation uptake [5,
6]. Schünemann and colleagues [7], for one, consider
implementation in policy and practice as part of the
guideline development process (steps 14 and 16).
Throughout this work, we will use guideline develop-
ment to encompass the guideline development and im-
plementation processes.
In recent years, we have witnessed considerable shifts
in how healthcare research is planned, delivered, shared,
and evaluated. It is now increasingly expected that indi-
viduals or groups involved in or affected by health- and
healthcare-related decisions, programs, or policies
(termed “stakeholders”) should have a say in the plan-
ning, conduct, dissemination, uptake, and evaluation of
healthcare research. In other words, stakeholders should
be engaged in the entire process of guideline develop-
ment. Several entities [8–11], including the World
Health Organization (WHO) and the National Institute
for Health and Care Excellence (NICE), recommend in-
volving stakeholders in guideline development. As such,
stakeholder engagement has become widely accepted in
the production of trustworthy guidelines [12, 13]. In
guideline development, stakeholder engagement is con-
sidered critical to ensuring priority guideline topics are
identified and that comprehensive assessments of the
evidence and other considerations are done [14–16].
Stakeholder involvement can help to ensure a guide-
line’s acceptability and feasibility to the end users. They
can also ensure that equity and human rights issues are
taken into consideration and support the adoption of its
recommendations into policy and practice. This in turn
may lead to improved adherence to any treatments and
practices recommended [7, 17]. Stakeholder engagement
in guideline development is part of a wider acceptance
by the research community of the value of ensuring the
participation of end users in the research and knowledge
translation cycles [18, 19]. There is a moral imperative
to engage end users in that people have a right to be in-
volved in activities that may affect them. End user en-
gagement may also improve the relevance, transparency,
and usefulness of guidelines [20].
There are many stakeholder groups equally affected by
recommendations in guidelines—e.g., patients, con-
sumers, providers, general public, researchers, and pol-
icymakers. However, engagement with patients/public/
community stakeholder groups dominates the literature,
and guidance of the engagement with patient/public
stakeholders is the most prominent [21–23]. In a review
of guideline methodologies conducted by Armstrong
and Bloom for example, patients/public stakeholders
were consulted by 101 different guideline developers
[21]. Many guideline groups that have sought to involve
stakeholders have utilized limited numbers of partici-
pants or utilized slow and labor-intensive processes (e.g.,
time and resources needed to administer, collate, and re-
spond to over 200 stakeholder views and comments)
[12]. It is recognized that successful guideline develop-
ment and implementation requires the engagement of
multiple stakeholders [24] and “shared solutions” (input
from patients, clinicians, and policymakers) improve
health outcomes [24–26]. Patient/public stakeholders
may potentially feel intimidated to contribute if they are
only one voice among many. Keeping patient and public
stakeholder voices separate from other stakeholder
groups potentially shortchanges the input and influence
that this group may offer. Equitable engagement of mul-
tiple stakeholder groups can help to ensure that guide-
lines contribute to reducing health disparities [27, 28].
However, there is a lack of consensus on how to identify
and recruit relevant stakeholders, how they should be
engaged, what their roles and responsibilities should be,
how to evaluate the impact of their engagement in
guideline development, and how to best collect and
manage conflicts of interest as part of the engagement
and guideline development process.
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Schünemann et al. identified 18 steps in the guide-
line development process, based on a review of 35
guideline manuals published between 2003 and 2013
[7]. Several manuals mentioned the importance of in-
cluding stakeholders, but few provided details on
what stakeholder engagement should entail. In a re-
view of 56 guidance documents for guideline develop-
ment, 72% mentioned incorporating patients and their
views in the process. However, the review did not
provide sufficient detail on how to do this for each
step of the guideline development process [29]. Arm-
strong et al. developed a framework for continuous
patient engagement in clinical practice guideline de-
velopment that outlines options for patient engage-
ment in the steps in which they are most commonly
involved [16]. While providing guidance on when to
involve patients, the framework does not provide
guidance on how to identify patients to participate
and does not discuss other stakeholders.
Effective stakeholder engagement, ideally, facilitates
the equitable contribution of relevant stakeholder
groups in the guideline development and implementa-
tion process. This requires that guideline developers es-
tablish processes that prevent more financially
powerful, highly vocal, or intellectually conflicted stake-
holder groups from dominating the guideline develop-
ment process. The Grading of Recommendations,
Assessment, Development and Evaluation (GRADE)
equity guidelines, for one, recommend the inclusion of
underrepresented stakeholder groups in the guideline
development and implementation process [30]. Stake-
holders will have various levels of time, resources, and
skills available to dedicate to the process, and ensuring
that these differences do not result in certain stake-
holder having more influence over the final guideline
recommendations is important. A challenging aspect of
engaging stakeholders is ensuring that interests are de-
clared and that conflicts of interest are appropriately
managed. Despite the importance of conflict of interest
for guideline development, there is high variability in
the process of disclosure and management of such con-
flicts across different organizations [27]. As a conse-
quence, there are many inconsistencies in how
stakeholder engagement is considered across guideline
development groups. There should be opportunities for
a variety of opinions to be heard, but it is vital that the
recommendations made are objective and not unduly
influenced by vested interests. Strategies such as active
outreach activities, giving adequate time for comment
on guideline recommendations and using processes
with follow-up prompts that ensure all stakeholder
comments are systematically addressed may assist in re-
ducing potential inequities and increase guideline de-
velopment transparency [12].
Study aim
The study aim is to develop guidance for guideline de-
velopers that supports the equitable and meaningful en-
gagement of multiple stakeholders throughout the
guideline development and implementation process.
Guideline development will be used to encompass devel-
opment, implementation, and evaluation processes. The
objectives, in terms of participants, interventions, and
comparators, are stakeholder/stakeholder groups en-
gaged in guideline development, engagement in the
guideline development process, and no comparator.
Outcomes are outlined below for each phase of the
project.
Key definitions
We define below the terms guideline, stakeholder, stake-
holder engagement, levels of engagement, and under-
represented groups used for this project.
Guideline
Guidelines are “systematically developed evidence-based
statements which assist providers, recipients, and other
stakeholders informed decisions about appropriate
health interventions” [31].
Stakeholder
A stakeholder is any “individual or group who is respon-
sible for or affected by health- and healthcare-related deci-
sions that can be informed by research evidence” [32].
Further, we acknowledge that some stakeholders may use
guidelines to inform decision-making (CIHR terms these
stakeholders, knowledge users), while others may have an
interest in the recommendations for other reasons [32–34].
We define eight stakeholder groups for this project, namely
(1) persons and the public (e.g., patients, their caregivers,
families, and patient and consumer advocacy organiza-
tions), (2) providers (individuals/organizations that provide
care, e.g., nurses, physicians, pharmacists, mental health
counselors, community-based workers), (3) payers (pays for
or reimburses for health-related interventions, e.g., insurers,
individuals with deductibles, others responsible for reim-
bursement for health-related interventions), (4) purchasers
(e.g., employers, self-insured, governments, and other
entities responsible for underwriting the cost of care), (5)
policymakers (policymaking entities such as governments
and professional associations), (6) product makers (e.g.,
drug/device manufacturers), (7) principal investigators (e.g.,
researchers), and (8) the press (e.g., publishers, news media)
[32, 33].
Engagement
“Engagement” refers to the approach to gather input or
contribution from stakeholders “toward the development
of a guideline, completion of any stages of a guideline,
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or dissemination, uptake or evaluation of a guideline and
its recommendations” [35]. Engagement is considered
multi-directional, resulting in “informed decision-
making about the selection, conduct, and use of the re-
search” [32]. Depending on the context, engagement
may also be termed collaboration, involvement, or part-
nership [36]. Herein, we will use the term “stakeholder
engagement.”
Levels of engagement (Table 1)
The extent to which stakeholders are engaged in the
guideline development process can vary. We identify
four levels of engagement (see Additional file 1), adapted
from previous work [37–39]: (1) Communication—stake-
holders receive information but have no role in contrib-
uting; (2) Consultation—stakeholders provide their
views, thoughts, feedback, opinions, or experiences but
without a commitment to act on them; (3) Collabor-
ation—stakeholders are engaged to influence the pro-
duction of the guidelines (e.g., commenting, advising,
ranking, voting, prioritizing, and reaching consensus)
but without direct control over decisions; and (4) Copro-
duction—stakeholders are equal members of the guide-
line development team and participate in all steps of the
guideline development process. Members benefit from
each other’s knowledge, skills, and perspectives and build
relationships in an open, trusting, and transparent atmos-
phere that encourages learning from each other. With on-
going collaboration and engagement, all members have an
equal opportunity to influence each aspect of the guideline
development process [25, 35, 37, 40–42].
Under-represented groups
Under-represented groups refer to those individuals or
groups who may experience health inequities for reasons
such as a lack of inclusion in research, health policy, or
guideline development; barriers to access of health ser-
vices; or because of other socially stratifying factors, such
as their place of residence, race/ethnicity/culture/
language, occupation, gender/sex, subject matter know-
ledge, religion, education, socioeconomic status, social
capital, age, or other individual characteristics [27, 28].
Study design and methods
We adapted our methods from the guidance for devel-
oping research reporting guidelines by Moher et al. [43]
and our internal Terms of Reference for GRADE project
groups document. Moher and colleagues recommend
identifying the need for guidance, reviewing the litera-
ture, identifying participants, conducting a Delphi survey
to gather opinions and set priorities, and holding a face-
to-face consensus meeting. We have made a slight modi-
fication by adding key informant interviews to gather
opinions on what should be included in the preliminary
guidance. The conception and design of the study is the
product of a global consortium for Multi-Stakeholder
Engagement, entitled MuSE.
The MuSE consortium
The MuSE consortium was established in 2015 and in-
cludes over 80 researchers and stakeholders in various
countries including: Australia, Brazil, Canada, Germany,
Italy, Lebanon, the Netherlands, the Philippines,
Switzerland, the UK, and the USA. The team includes
researchers, policymakers, guideline developers, research
funders, clinicians, patients and patient representatives,
and policymakers from various organizations including
the Agency for Healthcare Research and Quality
(AHRQ), the Campbell Collaboration, Cochrane,
GRADE Working Group, Health Canada, Patient-
Centered Outcomes Research Institute (PCORI), Re-
search and Development (RAND) Corporation, the
World Health Organization (WHO), Joanna Briggs Insti-
tute (JBI), and multiple universities. All team members
share an interest in developing methods and approaches
for involving patients and other stakeholders in health
outcomes research [44]. The MuSE consortium includes
three working groups with each undertaking projects
Table 1 Levels of engagement [37–39]
Level Description
Communication (level 1) Stakeholders receive information. Stakeholders may be present but have
no role in contributing.
e.g., “here’s what we are doing”
Consultation (level 2) Stakeholders provide their views, thoughts, feedback, opinions, or experiences
but without a commitment to act on them.
e.g., “What do you think about what
we are doing?”
Collaboration (level 3) Stakeholders are engaged to influence the production of guidelines (e.g.,
commenting, advising, ranking, voting, prioritizing, reaching consensus).
Stakeholders provide information which directly influences the guideline
process, but without direct control over decisions.
e.g., “Please get involved in what
we are doing”
Coproduction (level 4) Stakeholders are equal members of the guideline development team and
participate in all steps of the guideline development process. Stakeholders
work together in various roles throughout the guideline development process.
Stakeholders make collaborative decisions to shape the guideline
recommendations
e.g., “Let’s do it together”
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related to the development of methods for involving
multiple stakeholders in health outcomes research (see
Additional file 2).
Stakeholder engagement in the MuSE project
We will develop a stakeholder engagement framework for
this study that outlines how we will engage and evaluate
our own stakeholder engagement processes throughout
the project, drawing on principles of realist evaluation to
explore what works, for whom, why, and in what context
[45]. We have adopted a co-production approach, drawing
on the National Institute for Health Research (NIHR)
guidance which pays attention to sharing power, including
the perspectives and skills of all involved, respecting and
valuing the knowledge of all, reciprocity, and building and
maintaining relationships [25, 37, 40–42, 46]. We will
work with our stakeholder to agree on the best ways to
operationalize those key elements of co-production. We
have assembled a large, international project team of co-
investigators, collaborators, and stakeholders representing
the various stakeholder groups as part of the MuSE con-
sortium. All members of the consortium will be invited to
provide advice and collaborate throughout the planning of
each project stage, interpreting results, and coproducing
the final guidance paper. To ensure accurate and transpar-
ent reporting of our stakeholder engagement throughout
this project, we will follow the Guidance for Reporting In-
volvement of Patients and the Public (GRIPP2) checklist
[47]. We will document and report on the methods used
to engage our stakeholders, the results of the stakeholder
engagement, the extent to which stakeholders’ input influ-
enced the guidance development process and outcomes,
and the lessons learned from the experience [47].
GIN McMaster Guideline Development Checklist
This study will use the 18 steps contained in Schünemann
et al.’s Guidelines 2.0 checklist, known as the GIN McMas-
ter Guideline Development Checklist, for guideline devel-
opment as its organizing framework [7]. It provides
guideline developers with a comprehensive checklist of
items linked to relevant resources and tools to facilitate the
guideline development process. The GIN McMaster Guide-
line Development Checklist has been used by guideline de-
velopers in various settings and was used to develop
extensions for specific aspects of guideline development
such as adaptation and rapid guideline development [48–
52]. The 18 steps begin with the organization, budgeting,
and planning of the development process, and continue
with steps for priority setting, guideline group membership,
question generation, all the way to developing recommen-
dations, dissemination, implementation, and evaluation of
the guidelines. Item six on the checklist relates to consumer
and stakeholder involvement. As opposed to identifying
stakeholder engagement as one step along the multi-step
process of guideline development, the MuSE study will seek
to document evidence-based guidance for stakeholder en-
gagement for each step in the guideline development
process (see Additional file 3).
Equity and the PROGRESS-Plus framework
The Canadian Institutes for Health Research (CIHR) ex-
pects that all research applicants will integrate gender
and sex into their research designs when appropriate
[53]. The MuSE project recognizes gender as an import-
ant social determinant of health and contributor to
health inequities. Gender refers to “the socially con-
structed characteristics of women and men—such as
norms, roles, and relationships of and between groups of
women and men. It varies from society to society and
can be changed” [54]. Sex is “the different biological and
physiological characteristics of males and females, such
as reproductive organs, chromosomes, hormones, etc.”
[54]. Gender considerations will be integrated through-
out the MuSE project as part of the project’s adoption of
the PROGRESS-Plus framework for equity. The
PROGRESS-Plus framework identifies socially stratifying
factors that can contribute to health inequities [55]. We
define health inequities as difference in health status that
is avoidable, unfair, and unjust [56]. PROGRESS refers
to Place of residence, Race/ethnicity/culture/language,
Occupation, Gender/sex, Religion, Education, Socioeco-
nomic status, and Social capital. The Plus extends the
original framework to include personal characteristics
associated with discrimination (e.g., age, disability), fea-
tures of relationships (e.g., children of smoking parents),
and time-dependent relationships (e.g., release from in-
carceration) [55]. We will use the framework to guide
the integration of health equity considerations through-
out the project. Below, we describe the project stages
and the integration of equity in each.
Project stages
This study includes various stages (Fig. 1). Briefly, they
are (1) the conduct of four concurrent systematic re-
views, (2) the development of draft guidance, (3) an on-
line international survey of external stakeholders and
experts, (4) a consensus meeting of project stakeholders,
and (5) the finalization of the guidance paper. This
protocol focuses on stage 1.
Stage 1: Systematic reviews of the literature
We will conduct four systematic reviews to identify and
assess the available literature on stakeholder engagement
in guideline development. This protocol will yield four
distinct but related systematic reviews that will inform
the overall protocol output. To improve efficiency, we
will conduct an integrated literature search, screening,
and data extraction process. Once included, articles will
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be tagged for their relevance to a particular review(s).
Analyses and reports will be conducted separately for
each review. Given the qualitative and multi-stage na-
ture of this study, we believe the GRIPP2 checklist is
more suitable for reporting the conduct of this pro-
ject. The systematic review stage will be developed
following the PRISMA-P checklist (Additional file 4)
Below, we briefly describe the objectives of each review
and the methods common to all reviews.
Review 1: Existing guidance on stakeholder engage-
ment in guideline development
The objective of this review is to synthesize existing
guidance for stakeholder engagement at each of the
18 steps in the guideline development process. Eli-
gible studies will describe the development of a
framework or process for stakeholder engagement in
guideline development. This includes frameworks or
processes that address the implementation or evalu-
ation of stakeholder engagement in guideline develop-
ment. Outcomes to be synthesized are methods for
(1) identifying stakeholders, (2) engaging stakeholders
at different stages of the guideline development
process, and (3) resolving differences in opinions/per-
spectives. In addition, frequency and level of engage-
ment of stakeholders at each step of the guideline
development process, level of engagement in each
step of the guideline development process, and how
stakeholders contributed at each step of the guideline
development process will be synthesized.
Review 2: Barriers and facilitators to stakeholder en-
gagement in guideline development
The expected result of this review is to summarize
the barriers and facilitators to stakeholder engagement
at each step in the guideline development process.
Eligible studies will describe or assess the barriers
and facilitators to stakeholder engagement in
guideline development. A “barrier” is defined as any
variable or condition that impedes stakeholder en-
gagement in guideline development or implementa-
tion. A “facilitator” is defined as any variable or
condition that promotes stakeholder engagement in
guideline development or implementation.
Review 3: Conflicts of interest of multiple stakeholders
in guideline development
The objective is to systematically review the literature
on conflict of interest issues when engaging stakeholders
in guideline development. Specifically, this review aims
to answer the following questions: (1) What are the
types of conflicts of interest that stakeholders engaged in
the guideline development process have and how do
they vary by stakeholder group? (2) Can the conflicts of
interest of individuals or organizations selecting stake-
holders to participate in the development of a guideline
affect that selection process? (3) What are the potential
effect(s) of conflicts of interest of stakeholders on the
guideline development process? (4) What are the pro-
posed and/or implemented approaches for managing the
conflicts of interest of stakeholders engaged in guideline
development, and what are their respective advantages
and disadvantages?
Review 4: Impact of stakeholder engagement in guide-
line development
Fig. 1 Project plan
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This review will assess the impact of stakeholder en-
gagement in guideline development on (a) the guideline
development process; (b) guideline relevance, trust-
worthiness, acceptability, and uptake; and (c) the stake-
holders and panel members themselves. Eligible studies
will identify or assess the impact of multi-stakeholder
engagement through all the stages of guideline
development.
Eligibility Included studies will discuss stakeholder en-
gagement in guideline development that assesses existing
guidance and methods for stakeholder engagement at
each stage of the guideline development and implemen-
tation process, barriers and facilitators to stakeholder en-
gagement, conflicts of interest of stakeholders in the
guideline development and implementation process,
and/or impact of stakeholder engagement on the guide-
line development and implementation process.
Population For our purposes, stakeholders in guideline
development are as described above under the “Key defi-
nitions” section.
Intervention Eligible studies will involve/engage stake-
holders in some role(s) during the guideline develop-
ment process. Engagement and guidelines are as
described above under the “Key definitions” section.
Comparator Studies that do not involve stakeholders in
the guideline development process will not be eligible
for inclusion in this project.
Study designs All reviews will include quantitative,
qualitative, and mixed-methods studies. As such, our
methods will follow the Cochrane Handbook for Sys-
tematic Reviews of Interventions and the Handbook for
Synthesizing Qualitative Research, as appropriate [57,
58]. We will include randomized trials, non-randomized
studies (e.g., cohort studies, before and after studies,
cross-sectional studies), qualitative studies, theoretical
and ethical papers, process evaluation studies, policy
analysis studies, case studies, and mixed-methods stud-
ies. We will exclude editorials, commentaries, proposals,
and conference abstracts. Studies without a clear
methods section will be excluded.
Search strategy We will develop one comprehensive
search strategy to identify relevant studies for the four
reviews. We will search the following databases: MED-
LINE (OVID), CINAHL (EBSCO), EMBASE (OVID),
PsycInfo (OVID), AMED (OVID), and SCOPUS. We will
not place limits on language, date, or study design. In
addition, we will perform both backward and forward
citation tracking to identify further eligible studies. A
draft of the search strategy is provided (see Additional
file 5).
To identify grey literature, we will search the websites
of agencies who actively engage stakeholder groups such
as the AHRQ, Canadian Institute of Health Research
(CIHR) Strategy for Patient-Oriented Research (SPOR),
INVOLVE, the National Institute for Health and Care
Excellence (NICE), and the PCORI. We will also search
the websites of guideline-producing agencies, such as
the American Academy of Pediatrics, Australia’s Na-
tional Health Medical Research Council (NHMRC), and
the WHO. We will invite members of the team to sug-
gest grey literature sources, and we plan to broaden the
search by soliciting suggestions via social media, such as
Twitter (https://twitter.com/CochraneEquity).
Study selection Titles and abstracts of the studies iden-
tified by the search strategy and the full texts of those
assessed as potentially relevant will be screened inde-
pendently, in duplicate using Covidence software [38].
Disagreements on study selection will be resolved by dis-
cussion or with a third member of the research team
when necessary. Eligible studies will be exported into an
Excel spreadsheet and independently “tagged” for their
relevance to each review. One study may be included in
more than one review. For example, a study may de-
scribe a process for stakeholder engagement in guideline
development as well as describe the barriers and facilita-
tors to the stakeholder engagement.
Data extraction The data extraction form will be pre-
tested and will include (as applicable) factors related to
the population, intervention, comparison, and outcomes.
Extracted data common to all reviews include informa-
tion on study characteristics (e.g., year of publication,
authors, type of publication), stakeholders included,
stakeholder roles, and stakeholder characteristics. The
data will be extracted independently in duplicate by two
reviewers and will be piloted on ten articles. Disagree-
ments on extractions will be resolved by discussion and
with a third member of the research team when neces-
sary. Where necessary, the corresponding author of eli-
gible studies will be contacted for additional information
We will use the 18 steps of the guideline development
process as a framework for data extraction and will map
the existing guidance, barriers and facilitators, conflicts
of interest, and impacts discussed in our included stud-
ies to one or more of the steps of this framework [7].
Further, we will extract data that describe study popula-
tions and results or findings by PROGRESS-Plus factors.
Risk of bias We will examine the methodological qual-
ity of the included studies as appropriate. We will use
the risk of bias tools from the Cochrane Handbook for
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randomized trials (ROB2) [59], the Risk of Bias in Non-
randomized Studies – of Interventions (ROBINS-I) tool
[60], and the Critical Appraisal Skills Programme (CASP)
qualitative appraisal research tool [61] for qualitative stud-
ies. Risk of bias will be assessed independently, in dupli-
cate, by two authors, and any discrepancies will be
resolved by consensus and consultation with a third au-
thor, when necessary.
Analyses We will use a mixed-methods approach to
summarize our findings. Qualitative and quantitative
studies will be analyzed and synthesized separately, while
the implications for practice, policy, and research that
will form the discussion and conclusion sections of the
reviews will draw on both the qualitative and quantita-
tive syntheses. We will summarize findings across the
18-steps of the GIN-McMaster Checklist, the eight
stakeholder groups, and the PROGRESS-Plus factors.
We will report the systematic reviews following the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) [62] and the Enhancing Trans-
parency in Reporting the Synthesis of Qualitative Re-
search (ENTREQ) [63] reporting guidelines, as
appropriate. The GRADE or Confidence in the Evidence
from Reviews of Qualitative Research (CERQual) meth-
odology will be used to evaluate the quality of evidence
for each review as appropriate.
Stage 2: Drafting the guidance
In consultation with the MuSE consortium, we will use
the results of the four systematic reviews to develop a
candidate list of recommendations to include in the final
guidance paper. These draft recommendations will pro-
vide guidance mapped to the 18 steps of the guideline
development process which will allow guideline devel-
opers to consider when and how to engage different
stakeholders at each stage of the guideline development
process. Equity considerations at each step of the guide-
line development process will be outlined.
Drafting and refining the guidance will involve struc-
tured engagement similar to that described by Jull and
colleagues [64] with all MuSE consortium members. Be-
cause of our large and geographically diverse team, we
will consult with members via email, teleconferences,
and face-to-face meetings, as appropriate, to revise the
guidance and ensure that all team members have equal
opportunity to contribute and influence the research
output. We will work with our MuSE consortium mem-
bers to equitably include diverse voices in the drafting
process, including visible minorities, women, members
from low- and middle-income countries, and others who
are traditionally omitted from guideline development
processes.
Discussion
Stakeholder engagement should be multidirectional,
meaningful, effective, and enable equity for both the
stakeholders and guideline developers throughout all
steps in the decision-making process. This project is in-
novative in that we are committed to an inclusive, com-
prehensive, and equitable approach to ensure that the
guidance we develop is representative and relevant for
all stakeholders, including those who are involved in cre-
ating and implementing guidelines and those affected by
the recommendations developed within those guidelines.
Our stakeholder engagement strategy for the project will
assist us in effectively engaging our own stakeholders
and allow us to monitor our engagement processes in
real-time so that course corrections can be made if there
is evidence of non-meaningful engagement.
We are not including language or date restrictions on
our search strategy. A potential limitation of these re-
views is that we are including papers regardless of their
methodological quality. This will allow us to collect and
synthesize qualitative data that we may miss if standard
methodological criteria are applied. We will discuss limi-
tations further in the full review.
These reviews will contribute to the literature by identi-
fying existing guidance, barriers and facilitators, potential
impacts, and possible conflict of interest issues related to
engagement of stakeholders from many stakeholder
groups in guideline development and implementation.
The results of the four reviews will inform the devel-
opment of draft guidance. Once drafted, we will gather
opinions and priorities on the guidance items from a
wide range of purposefully selected stakeholders external
to the MuSE consortium, including representation from
low- and middle-income countries through an anonym-
ous, online survey. We will strive for equity in the iden-
tification of survey recipients by engaging with a
diversity of respondents representing different physical
capabilities, genders, geographies, socio-economic sta-
tuses, and ethnicities. We will then present the results of
the survey for each candidate item and use structured
discussions to reach consensus on the included items for
the final guidance paper at a two-day face-to-face con-
sensus meeting as recommended by Moher et al. [43].
Finally, based on the results of the previous stages, we
will develop guidance that provides recommendations
for stakeholder roles and modes of engagement at differ-
ent steps of the guideline development process (includ-
ing implementation and evaluation) and for managing
conflicts of interest. We will use an iterative process of
feedback to draft, refine, and finalize the guidance to be
provided in each manuscript in consultation with the
co-authors of each paper and the other members of the
MuSE consortium. The final product will be included in
GRADE Working Group Guidance. The GRADE
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Working Group has developed internationally recog-
nized guidance for the development of clinical practice
and public health guidelines [65].
The expected final guidance will contribute to improv-
ing the guideline development and implementation
process by identifying strategies for the meaningful and
equitable engagement of all relevant stakeholder groups
at all stages. Through this project, we aim to contribute
to the growing body of literature on stakeholder engage-
ment for better quality guidance, increased uptake of
guidance, more relevant health programs, policies and
services, and more equitable health outcomes.
We continually welcome additional expressions of
interest and suggestions for relevant literature and plan
to evaluate our own stakeholder engagement throughout
this work to ensure meaningful engagement.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-020-1272-5.
Additional file 1: Table S1. Levels of engagement.
Additional file 2. The MuSE Consortium.
Additional file 3. PRISMA-P reporting checklist.
Additional file 4. Stakeholders across the 18 steps.
Additional file 5. Draft Search Strategy in Medline.
Abbreviations
AHRQ: Agency for Healthcare Research and Quality; CASP: Critical Appraisal
Skills Programme; CERQual: Confidence in the Evidence from Reviews of
Qualitative Research; CIHR: Canadian Institute of Health Research;
ENTREQ: Enhancing Transparency in Reporting the Synthesis of Qualitative
Research; GRADE: Grading of Recommendations, Assessment, Development
and Evaluation; GRIPP: Guidance for Reporting Involvement of Patients and
the Public; JBI: Joanna Briggs Institute; MuSE: Multi-stakeholder engagement;
NICE: National Institute for Health and Care Excellence; NIHR: National
Institute for Health Research; PCORI: Patient-Centered Outcomes Research
Institute; PRISMA: Preferred Reporting Items for Systematic Reviews and
Meta-Analysis; PROGRESS: Place of residence, Race/ethnicity/culture/
language, Occupation, Gender/sex, Religion, Education, Socioeconomic
status, and Social capital; ROB: Risk of bias; ROBINS-I: Risk of Bias in Non-
randomized Studies – of Interventions; SPOR: Strategy for Patient-Oriented
Research; WHO: World Health Organization
Acknowledgements
We would like to thank the entire MuSE consortium membership for their
valuable contributions and advice.
Authors’ contributions
PT conceived the project, and JP wrote the first draft of this manuscript. JP,
EAA, AS, PC, KC, SMC, SC, LD, DG, IDG, SG, JMG, JJ, EVL, AL, LM, RM, RAM, JPP,
AP, KP, HS, VW, HW, TWC, and PT contributed to the grant proposal that
initiated this project. JP, AR, TWC, LL, JK, EAA, RS, PA, and VW held regular
project development meetings. ATS, MS, JR, SVK, JJ, TWC,RGS, PA, SC, VW,
FEJ, FN, AP, JMG, IDG, EVL, JT, GH, SMC, PC, AR, JP, and EAA contributed to
subsequent revisions to the manuscript. JP will lead the systematic review
on existing guidance, AR will lead the systematic review of barriers and
facilitators, LL will lead the systematic review on impact, and JK will lead the
systematic review on conflicts of interest. All authors commented on each
version of the draft manuscript. All authors approved the final manuscript. JP
is the manuscript guarantor.
Funding
This work has been funded by the Canadian Institutes of Health Research
(PJT-155970; Application number: 391110). AS is supported by a National
Health and Medical Research Council Postgraduate Scholarship (GNT
1132803). SVK is funded by a NRS Senior Clinical Fellowship (SCAF/15/02),
the Medical Research Council (MRC_UU_12017/13 & MRC_UU_12017/15),
and the Scottish Government Chief Scientist Office (SPHSU13 & SPHSU15).
PC and AP are employed by the Nursing, Midwifery and Allied Health
Professions Research Unit, which is funded by the Chief Scientist Office in
Scotland. IDG is a recipient of a Canadian Institutes of Health Research
Foundation Grant (FDN# 143237). The funders had no role in study design,
preparation of manuscript, or the decision to publish.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated
or analyzed during the current study.
Ethics approval and consent to participate
The international online survey stage of the study will be submitted to the
Bruyère Research Institute’s Ethics Review Board for approval prior to
launching the survey.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Author details
1Bruyère Research Institute, Bruyère Continuing Care and University of
Ottawa, 85 Primrose Ave East, Ottawa, Ontario, Canada. 2Department of
Internal Medicine, American University of Beirut, Beirut, Lebanon. 3Clinical
Research Institute, American University of Beirut, Beirut, Lebanon. 4McMaster
University, Hamilton, Ontario, Canada. 5Bruyère Research Institute, 85
Primrose Ave East, Ottawa, Ontario, Canada. 6Nursing, Midwifery and Allied
Health Professions (NMAHP) Research Unit, Glasgow Caledonian University,
Glasgow, UK. 7Faculty of Medicine, School of Public Health Imperial College,
London, UK. 8Agency for Healthcare Research and Quality, Rockville, MD,
USA. 9Crowe Associates Ltd., Oxford, UK. 10Department of Clinical
Epidemiology, University of the Philippines-Manila, Taft Ave, 1000 Manila,
Philippines. 11American University of Beirut, Beirut, Lebanon. 12National
Health and Medical Research Council, Canberra, Australia. 13School of
Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
14Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. 15Department
of Social & Behavioral Sciences, Richard M. Fairbanks School of Public Health,
Indiana University, 1050 Wishard Blvd, RG 6046, Indianapolis, IN 46202, USA.
16LLC/S.T.A.R. Initiative, Apple Valley, CA, USA. 17Departments of Obstetrics
and Gynecology, Medical Informatics & Clinical Epidemiology, Emergency
Medicine Oregon Health & Science, University School of Medicine and the
OHSU-PSU School of Public Health, Portland, USA. 18University of Calgary,
Calgary, Canada. 19School of Rehabilitation Therapy, Faculty of Health
Sciences, Queen’s University, Kingston, Ontario, Canada. 20MRC/CSO Social &
Public Health Sciences Unit, University of Glasgow, 200 Renfield Street,
Glasgow G2 3AX, UK. 21Alliance for Health Policy and Systems Research,
World Health Organization, Geneva, Switzerland. 22Cochrane Musculoskeletal
Group, London, Ontario, Canada. 23University of Ottawa, Ottawa, Canada.
24The Cochrane Collaboration, Cochrane Consumer Network, London, UK.
25Department of Internal Medicine/Division of Nephrology and Hypertension,
University of Kansas Medical Center, Kansas, USA. 26Unit of Epidemiology and
Statistics, IRCCS - Institute of Neurological Sciences of Bologna, Bologna, Italy.
27Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Canada.
28Nursing Midwifery and Allied Health Professions (NMAHP) Research Unit,
Glasgow Caledonian University, Glasgow, UK. 29Departments of Family
Medicine and Epidemiology and Public Health, University of Ottawa, Ottawa,
Canada. 30Primary Care Research Group and Equity Methods Group, Bruyère
Research Institute, Ottawa, Canada. 31Department of Family Medicine,
McMaster University, Hamilton, Ontario, Canada. 32Department of Health
Research Methods, Evidence, and Impact, Cochrane Canada and McMaster
GRADE Centre, Hamilton, Canada. 33Cochrane Consumer Executive, Ottawa,
Ontario, Canada. 34Programa de Pós-Graduação em Ciências da Saúde,
Universidade Federal de Ciências da Saúde de Porto Alegre - UFCSPA, Rua
Petkovic et al. Systematic Reviews            (2020) 9:21 Page 9 of 11
Sarmento Leite 245, Porto Alegre, RS 90050-170, Brazil. 35Centre for Health
Communication and Participation, School of Psychology and Public Health,
La Trobe University, Melbourne, Australia. 36Cochrane Australia, School of
Public Health and Preventive Medicine, Monash University, Melbourne,
Australia. 37PCORI, Seattle, USA. 38Alfred Deakin University, Geelong, Australia.
39Journal of Development Studies and Journal of Development Effectiveness,
Geelong, Victoria, Australia. 40The Campbell Collaboration, Oslo, Norway.
41The RAND Corporation, Boston, MA, USA. 42Tufts Clinical & Translational
Science Institute, Tufts University School of Medicine, Boston, MA, USA.
43University of Ottawa, Department of Medicine, Faculty of Medicine, Ottawa,
Canada. 44Ottawa Hospital Research Institute, Clinical Epidemiology Program,
Ottawa, Canada. 45University of Ottawa, School of Epidemiology and Public
Health, Faculty of Medicine, Ottawa, Canada.
Received: 6 August 2019 Accepted: 6 January 2020
References
1. WHO. WHO Handbook for Guideline Development – 2nd Edition [Internet].
World Health Organization, Geneva, Switzerland; 2014 [cited 2019 Apr 5].
Available from: http://apps.who.int/medicinedocs/en/m/abstract/Js22083en/
2. Kredo T, Bernhardsson S, Machingaidze S, Young T, Louw Q, Ochodo E,
et al. Guide to clinical practice guidelines: the current state of play. Int J
Qual Health Care J Int Soc Qual Health Care. 2016 Feb;28(1):122–8.
3. Institute of Medicine (US) Committee on Standards for Developing
Trustworthy Clinical Practice Guidelines. Clinical practice guidelines we can
trust [Internet]. Graham R, Mancher M, Miller Wolman D, Greenfield S,
Steinberg E, editors. Washington (DC): National Academies Press (US); 2011
[cited 2019 Apr 5]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK2
09539/
4. Sonnad SS. Organizational tactics for the successful assimilation of medical
practice guidelines. Health Care Manage Rev. 1998;23(3):30–7.
5. Moulding NT, Silagy CA, Weller DP. A framework for effective management
of change in clinical practice: dissemination and implementation of clinical
practice guidelines. BMJ Qual Saf. 1999 Sep 1;8(3):177–83.
6. Gagliardi AR, Brouwers MC. Integrating guideline development and
implementation: analysis of guideline development manual instructions for
generating implementation advice. Implement Sci IS. 2012 Jul 23;7:67.
7. Schünemann HJ, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa
R, et al. Guidelines 2.0: systematic development of a comprehensive
checklist for a successful guideline enterprise. CMAJ Can Med Assoc J J
Assoc Medicale Can. 2014;186(3):E123–42.
8. Jarret L, Patient Involvement Unit. A report on a study to evaluate patient/
carer membership of the first NICE Guideline Development Groups
[Internet]. National Institute for Clinical Excellence; 2004 [cited 2019 Apr 24].
Available from: https://www.nice.org.uk/media/default/About/NICE-
Communities/Public-involvement/Public-involvement-programme/PIU-GDG-
evaluation-report-2004-1.pdf
9. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees
P, et al. Guidelines International Network: toward international standards for
clinical practice guidelines. Ann Intern Med. 2012 Apr 3;156(7):525–31.
10. Schünemann HJ, Fretheim A, Oxman AD, WHO. Advisory Committee on
Health Research. Improving the use of research evidence in guideline
development: 1. Guidelines for guidelines. Health Res Policy Syst. 2006 Nov
21;4:13.
11. Guidelines I of M (US) C on S for DTCP, Graham R, Mancher M, Wolman DM,
Greenfield S, Steinberg E. Committee on standards for developing
trustworthy clinical practice guidelines [Internet]. National Academies Press
(US); 2011 [cited 2019 Apr 24]. Available from: https://www.ncbi.nlm.nih.
gov/books/NBK209544/
12. Cluzeau F, Wedzicha JA, Kelson M, Corn J, Kunz R, Walsh J, et al. Stakeholder
involvement: how to do it right: article 9 in integrating and coordinating
efforts in COPD guideline development. An official ATS/ERS workshop
report. Proc Am Thorac Soc. 2012 Dec;9(5):269–73.
13. NHMRC. 2016 NHMRC Standards for Guidelines | NHMRC [Internet]. 2016
[cited 2019 Apr 5]. Available from: https://www.nhmrc.gov.au/about-us/
publications/2016-nhmrc-standards-guidelines
14. Gillard S, Simons L, Turner K, Lucock M, Edwards C. Patient and public
involvement in the coproduction of knowledge: reflection on the analysis
of qualitative data in a mental health study. Qual Health Res. 2012 Aug;
22(8):1126–37.
15. Oliver K, Lorenc T, Innvær S. New directions in evidence-based policy
research: a critical analysis of the literature. Health Res Policy Syst. 2014;
12:34.
16. Armstrong MJ, Rueda J-D, Gronseth GS, Mullins CD. Framework for
enhancing clinical practice guidelines through continuous patient
engagement. Health Expect Int J Public Particip Health Care Health Policy.
2017;20(1):3–10.
17. Carroll C. Qualitative evidence synthesis to improve implementation of
clinical guidelines. BMJ. 2017 Jan 16;356:j80.
18. Jackson CL, Greenhalgh T. Co-creation: a new approach to optimising
research impact? Med J Aust. 2015 Oct 5;203(7):283–4.
19. Ghaffar A, Langlois EV, Rasanathan K, Peterson S, Adedokun L, Tran NT.
Strengthening health systems through embedded research. Bull World
Health Organ. 2017 01;95(2):87.
20. Esmail L, Moore E, Rein A. Evaluating patient and stakeholder engagement in
research: moving from theory to practice. J Comp Eff Res. 2015 Mar;4(2):133–45.
21. Armstrong MJ, Bloom JA. Patient involvement in guidelines is poor five
years after institute of medicine standards: review of guideline
methodologies. Res Involv Engagem. 2017;3(1):19.
22. Lavis JN, Paulsen EJ, Oxman AD, Moynihan R. Evidence-informed health
policy 2 – Survey of organizations that support the use of research
evidence. Implement Sci. 2008;3(1):54.
23. van de Bovenkamp HM, Zuiderent-Jerak T. An empirical study of patient
participation in guideline development: exploring the potential for
articulating patient knowledge in evidence-based epistemic settings. Health
Expect. 2015;18(5):942–55.
24. Suman A, Dikkers MF, Schaafsma FG, van Tulder MW, Anema JR.
Effectiveness of multifaceted implementation strategies for the
implementation of back and neck pain guidelines in health care: a
systematic review. Implement Sci. 2016 Sep 20;11(1):126.
25. Dunston R, Lee A, Boud D, Brodie P, Chiarella M. Co-production and health
system reform - from re-imagining to re-making. Aust J Public Adm. 2009;
68(1):39–52.
26. Kumarasamy MA, Sanfilippo FP. Breaking down silos: engaging students to
help fix the US health care system. J Multidiscip Healthc. 2015;8:101–8.
27. Shi C, Tian J, Wang Q, Petkovic J, Ren D, Yang K, et al. How equity is
addressed in clinical practice guidelines: a content analysis. BMJ Open. 2014;
4(12):e005660.
28. Wallerstein N, Duran B. Community-based participatory research contributions
to intervention research: the intersection of science and practice to improve
health equity. Am J Public Health. 2010 Apr 1;100 Suppl 1:S40-S46.
29. Selva A, Sanabria AJ, Pequeño S, Zhang Y, Solà I, Pardo-Hernandez H, et al.
Incorporating patients’ views in guideline development: a systematic review
of guidance documents. J Clin Epidemiol. 2017;88:102–12.
30. Akl EA, Welch V, Pottie K, Eslava-Schmalbach J, Darzi A, Sola I, et al. GRADE
equity guidelines 2: considering health equity in GRADE guideline
development: equity extension of the guideline development checklist. J
Clin Epidemiol. 2017;90:68–75.
31. Global Programme on Evidence for Health Policy. Guideline for WHO
Guidelines [Internet]. World Health Organization, Geneva, Switzerland; 2003
[cited 2019 Apr 24]. Available from: http://archives.who.int/eml/expcom/
expcom14/1other/guid_for_guid.pdf
32. Concannon TW, Meissner P, Grunbaum JA, McElwee N, Guise J-M, Santa J,
et al. A new taxonomy for stakeholder engagement in patient-centered
outcomes research. J Gen Intern Med. 2012;27(8):985–91.
33. Tugwell P, Robinson V, Grimshaw J, Santesso N. Systematic reviews and
knowledge translation. Bull World Health Organ. 2006;84(8):643–51.
34. Canadian Institutes of Health Research. Guide to knowledge translation
planning at CIHR: integrated and end-of-grant approaches [Internet].
Ottawa, Ontario; 2012 [cited 2019 May 29]. Available from: http://www.cihr-
irsc.gc.ca/e/documents/kt_lm_ktplan-en.pdf, http://www.cihr-irsc.gc.ca/e/
documents/kt_lm_ktplan-en.pdf
35. Pollock A, Campbell P, Struthers C, Synnot A, Nunn J, Hill S, et al. Stakeholder
involvement in systematic reviews: a scoping review. Syst Rev. 2018;7(1):208.
36. Hoddinott P, Pollock A, O’Cathain A, Boyer I, Taylor J, MacDonald C, et al.
How to incorporate patient and public perspectives into the design and
conduct of research. F1000Research. 2018 Jun 18;7:752.
37. Oliver SR, Rees RW, Clarke-Jones L, Milne R, Oakley AR, Gabbay J, et al. A
multidimensional conceptual framework for analysing public involvement in
health services research. Health Expect Int J Public Particip Health Care
Health Policy. 2008;11(1):72–84.
Petkovic et al. Systematic Reviews            (2020) 9:21 Page 10 of 11
38. Pollock A, Campbell P, Struthers C, Synnot A, Nunn J, Hill S, et al.
Development of the ACTIVE framework to describe stakeholder
involvement in systematic reviews. J Health Serv Res Policy. 2019;18:
1355819619841647.
39. Crowe S. “Who inspired my thinking?- Sherry Arnstein.” Res All. 2017;1(1):
143-146(4).
40. INVOLVE-National Institute for Health Research. Guidance on co-producing a
research project [Internet]. Hampshire, UK; 2018 [cited 2019 Jun 7]. Available
from: https://www.invo.org.uk/posttypepublication/guidance-on-co-
producing-a-research-project/
41. Markkanen S, Burgess G. Introduction to co-production in research:
summary report; 2016.
42. Pohl C, Rist S, Zimmermann A, Fry P, Gurung GS, Schneider F, et al.
Researchers’ roles in knowledge co-production: experience from
sustainability research in Kenya, Switzerland. Bolivia and Nepal. Sci Public
Policy. 2010;37(4):267–81.
43. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health
research reporting guidelines. PLoS Med. 2010;7(2):e1000217.
44. Concannon TW, Grant S, Welch V, Petkovic J, Selby J, Crowe S, et al.
Practical guidance for involving stakeholders in health research. J Gen
Intern Med. 2019;34(3):458–63.
45. Wilson P, Mathie E, Keenan J, McNeilly E, Goodman C, Howe A, et al.
ReseArch with Patient and Public invOlvement: a RealisT evaluation – the
RAPPORT study [Internet]. Southampton (UK): NIHR Journals Library; 2015
[cited 2019 Jun 12]. (Health Services and Delivery Research). Available from:
http://www.ncbi.nlm.nih.gov/books/NBK315999/
46. National Institute for Health Research. National Standards for Public
Involvement In Research [Internet]. 2018 [cited 2019 Jun 12]. Available from:
https://www.nihr.ac.uk/news-and-events/documents/Public_Involvement_
Standards_March%202018_WEB.pdf
47. Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al.
GRIPP2 reporting checklists: tools to improve reporting of patient and
public involvement in research. Res Involv Engagem. 2017;3:13.
48. Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C,
Jaramillo E, et al. World Health Organization treatment guidelines for drug-
resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3).
49. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA,
Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic
and transparent approach to making well informed healthcare choices. 2:
Clinical practice guidelines. BMJ. 2016 Jun 30;353:i2089.
50. Fiocchi A, Pawankar R, Cuello-Garcia C, Ahn K, Al-Hammadi S, Agarwal A,
et al. World Allergy Organization-McMaster University guidelines for allergic
disease prevention (GLAD-P): probiotics. World Allergy Organ J. 2015;8(1):4.
51. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R,
et al. SCENIC international consensus statement on surveillance and
management of dysplasia in inflammatory bowel disease. Gastrointest
Endosc. 2015 Mar;81(3):489-501.e26.
52. Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are
priorities for deprescribing for elderly patients? Capturing the voice of
practitioners: a modified delphi process. PloS One. 2015;10(4):e0122246.
53. Canadian Institutes of Health Research. How to integrate sex and gender
into research [Internet]. 2018 [cited 2019 Jun 11]. Available from: http://
www.cihr-irsc.gc.ca/e/50836.html
54. World Health Organization. Gender mainstreaming for health managers: a
practical approach [Internet]. Geneva : World Health Organisation; 2011 [cited
2019 Jun 11]. Available from: https://apps.who.int/iris/handle/10665/44516
55. O’Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying
an equity lens to interventions: using PROGRESS ensures consideration of
socially stratifying factors to illuminate inequities in health. J Clin Epidemiol.
2014 Jan 1;67(1):56–64.
56. Whitehead M. The concepts and principles of equity and health. Int J
Health Serv. 1992;22(3):429–45.
57. Sandelowski M, Barroso J. Handbook for synthesizing qualitative research.
New York: Springer Publishing Company; 2007. 284 p.
58. Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of
Interventions [Internet]. The Cochrane Collaboration; 2011 [cited 2019 Apr
5]. Available from: https://handbook-5-1.cochrane.org/
59. Higgins JPT, Sterne JAC, Savović j., Page MJ, Hróbjartsson A, Boutron I, et al.
Appraising the risk of bias in randomized trials using the Cochrane Risk of
Bias Tool. In: Cochrane Methods 2016 J Chandler, J McKenzie, I Boutron and
V Welch (editors) Cochrane Database of Systematic Reviews 10 (Suppl 1)
[Internet]. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1
002/14651858.CD201601/full
60. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M,
et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of
interventions. BMJ. 2016;355:i4919.
61. Critical Appraisal Skills Programme. Casp Checklists. Casp. 2013.
62. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al.
The PRISMA statement for reporting systematic reviews and meta-analyses
of studies that evaluate health care interventions: explanation and
elaboration. PLoS Med. 2009;6(7):e1000100.
63. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in
reporting the synthesis of qualitative research: ENTREQ. BMC Med Res
Methodol. 2012;12:181.
64. Jull J, Petticrew M, Kristjansson E, Yoganathan M, Petkovic J, Tugwell P, et al.
Engaging knowledge users in development of the CONSORT-Equity 2017
reporting guideline: a qualitative study using in-depth interviews. Res Involv
Engagem. 2018;4:34.
65. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The
GRADE Working Group clarifies the construct of certainty of evidence. J Clin
Epidemiol. 2017;87:4–13.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Petkovic et al. Systematic Reviews            (2020) 9:21 Page 11 of 11
